Examkin

Question

Difficulty: EasyGastroenterology and Hepatology

A 6161-year-old man with known liver cirrhosis secondary to chronic hepatitis C infection is hospitalized due to an acute onset of fever, diffuse abdominal discomfort, and confusion. Diagnostic paracentesis performed on the day of admission yielded ascitic fluid with an absolute neutrophil count of 550550 cells/mm 3^3. Consequently, he was initiated on an empiric antimicrobial regimen of intravenous piperacillin-tazobactam and vancomycin.

Now, on his third day in the hospital, his clinical status has markedly improved. He is fully oriented, his temperature is 37.0∘37.0^\circ C (98.6∘98.6^\circ F), and his abdominal pain has subsided. The ascitic fluid cultures from admission demonstrate the growth of *Escherichia coli*. The susceptibility report indicates that this organism is resistant to ampicillin but highly susceptible to ceftriaxone, cefotaxime, and ciprofloxacin.

Which of the following is the most appropriate next step in management?

  1. A
    Maintain the current regimen of intravenous piperacillin-tazobactam and vancomycin
  2. B
    Discontinue vancomycin but maintain intravenous piperacillin-tazobactam
  3. Switch the antimicrobial regimen to intravenous ceftriaxoneAnswer
  4. D
    Switch the antimicrobial regimen to intravenous meropenem
  5. E
    Add intravenous fluconazole to the current antimicrobial regimen

Answer

Switch the antimicrobial regimen to intravenous ceftriaxone
The correct answer demonstrates the appropriate application of antibiotic stewardship in a patient with spontaneous bacterial peritonitis (SBP). The patient was initially treated appropriately with broad-spectrum antibiotics (piperacillin-tazobactam and vancomycin), which is indicated for critically ill patients with severe infections. However, once clinical improvement is noted and specific culture data identify a susceptible pathogen (*E. coli* sensitive to ceftriaxone), the standard of care requires de-escalating to a narrower-spectrum, targeted agent. Ceftriaxone provides excellent coverage for this infection while minimizing adverse effects and selective pressure for resistance.

Step-by-Step Solution

1
Identify the patient's current clinical status and initial diagnosis.
The patient was diagnosed with spontaneous bacterial peritonitis (SBP) and is now clinically stable after three days of empiric broad-spectrum therapy.
Establishing the clinical trajectory is necessary to decide whether therapy can be safely modified.
2
Analyze the ascitic fluid culture and susceptibility results.
The culture grew *Escherichia coli* that is sensitive to ceftriaxone, cefotaxime, and ciprofloxacin.
Culture data provides the definitive microbiological diagnosis and guides targeted pharmacotherapy.
3
Apply the principles of antibiotic stewardship to determine the next step.
The current broad-spectrum regimen (piperacillin-tazobactam and vancomycin) should be de-escalated to a narrow-spectrum agent (ceftriaxone).
Targeted therapy minimizes toxicity, reduces the risk of superinfections, and prevents the development of antimicrobial resistance.

Key Concept

In patients treated empirically for spontaneous bacterial peritonitis who demonstrate clinical improvement, the antibiotic regimen should be de-escalated to a targeted, narrower-spectrum agent as soon as culture and susceptibility results are available.
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic